![]() ![]() Whether you are seeking to start a drug monitoring program or to supplement an existing program with additional testing, we offer urine and oral fluid drug testing to meet the needs of healthcare providers, pain specialists, behavioral health specialists, and health systems. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.Drug misuse often occurs unintentionally in any population, which is why we offer a broad array of drug testing for your diverse needs. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. In the last reported quarter, it delivered an average earnings surprise of 108.9%.įrom thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. ![]() PODD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 100.1%. Shares of the company have decreased 42% in the past year against the industry’s growth of 11.7%. In the last reported quarter, it posted an earnings surprise of 16.7%.Įstimates for Insulet’s 2024 earnings per share have increased from $2.54 to $3.03 in the past 30 days. Earnings estimates for CAH have increased from $6.91 to $7.28 in fiscal 2024 and increased from $7.76 to $8.03 in fiscal 2025 in the past 30 days.ĬAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it delivered an average earnings surprise of 22.2%.Ĭardinal Health’sstock has risen 49.9% in the past year. Shares of the company have risen 56.7% in the past year compared with the industry’s growth of 18.1%.ĭVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. Įstimates for DaVita’s 2024 earnings per share have advanced from $8.46 to $8.97 in the past 30 days. You can see the complete list of today’s Zacks #1 Rank stocks here. DaVita presently sports a Zacks Rank #1 (Strong Buy), while Cardinal Health and Insulet carry a Zacks Rank #2 (Buy) each at present. ![]() Some better-ranked stocks in the broader medical space are DaVita DVA, Cardinal Health CAH and Insulet PODD. The company boasts a robust pipeline of professional lab services and M&A opportunities, which, along with business strength, will help in the continued growth of base volume. The business is also benefiting from the continued return to care. The collaborations with health plans, hospitals and physicians have increased demand for its services. Quest Diagnostics is also benefiting from strong volume growth across its base business (which refers to testing volumes, excluding COVID-19 testing). The company also recently announced collaborations with the Rutgers Cancer Institute to use the test in their clinical study of early-stage triple-negative breast cancer. In 2024, Quest Diagnostics is set to launch its first MRD test following the acquisition of Haystack Oncology. Throughout 2023, the company advanced its growth strategy with innovative testing solutions, new and expanded relationships with health systems and a robust pipeline of M&A and professional lab services opportunities. It also enables faster growth across all customer channels through advanced diagnostics with an intense focus on faster-growing clinical areas, including molecular genomics and oncology. The company prioritizes delivering solutions that meet the evolving needs of its core customers, including physicians, hospitals and consumers. On a positive note, Quest Diagnostics aims to accelerate revenue growth as part of its two-point business strategy. Quest Diagnostics Incorporated price | Quest Diagnostics Incorporated Quote As a result, Quest Diagnostics and other commercial labs compete with hospital-affiliated labs, primarily based on the quality of service. While pricing is an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service, including an accurate and rapid turnaround of testing results. ![]() A higher debt level induces higher interest payments, which comes along with the risk of failure to pay the same.įurther, Quest Diagnostics faces intense competition, primarily from LabCorp and other commercial laboratories and hospitals. The current portion of the debt was also much higher at $303 million. At the end of the fourth quarter of 2023, the long-term debt was $4.41 billion, while the cash and cash equivalent balance was only $686 million. Added to this, the company’s solvency level remains a concern. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |